Placebo-controlled, randomized trial of fluoxetine in the treatment of aggression in male intimate partner abusers.
Placebo-controlled, randomized trial of fluoxetine in the treatment of aggression in male intimate partner abusers.
复制标题
氟西汀治疗男性亲密伴侣施虐者攻击行为的安慰剂对照、随机试验。
DOI：
10.1097/yic.0b013e32830fbdd2
复制
发表时间：
2008
影响因子：
2.6
通讯作者：
Coccaro,EmilF
中科院分区：
文献类型：
--
作者：
Lee,Royce;Kavoussi,RichardJ;Coccaro,EmilF
目的是确定氟西汀治疗有亲密伴侣虐待史的男性攻击行为的疗效。26名有亲密伴侣虐待行为史的男性进入了一项随机、安慰剂对照的氟西汀试验（每天口服20-60 mg）。主要结果测量是来自改良的公开攻击量表（OAS-M）的攻击评分。氟西汀治疗的患者（n= 13）与安慰剂治疗的患者（n = 13）在任何关键人口统计学或行为变量方面均无差异。尽管在所有患者中观察到OAS-M攻击性评分的显著“前后”降低，但在任何分析中均未观察到OAS-M攻击性评分的药物-安慰剂差异。尽管样本很小，但这些结果并不支持这样的假设，即SSRI治疗与有亲密伴侣虐待史的男性的攻击行为减少有关。
The objective was to determine the efficacy of treating aggressive behavior in men, with a history of intimate partner abuse, with fluoxetine. Twenty-six men with a history of intimate-partner-abusing behavior entered a randomized, placebo-controlled trial of fluoxetine (20–60 mg by mouth per day). The primary outcome measure was the Aggression score from the overt aggression scale-modified (OAS-M). Fluoxetine-treated patients (n= 13) did not differ from placebo-treated patients (n= 13) on any key demographic or behavioral variables. Although a significant ‘pre–post’reduction in OAS-M Aggression score was noted in all patients, no drug–placebo differences for OAS-M Aggression scores were seen in any analysis. Despite the small sample, these results do not support the hypothesis that treatment with an SSRI is associated with a reduction in aggressive behavior among men with a history of intimate partner abuse.